Author index

H. Abacıoğlu, 736
B. Acosta, 725
C. Adalid, 50
S. A. Adams, 529
S. J. Advani, 551
P. Aerts, 246
J. M. Aguado, 125
K. Ahmed, 55
M. Akova, 240
Y. Akyön, 438
J. I. Alós, 745
A. Al-Aniezi, 734
B. Al-Nawas, 93
M. Aliani, 358
M. N. Almuzara, 828
R. Alonso, 447
B. Altun, 240
V. Anand, 2
A. W. Anderson, 174
A. Andremont, 405
F. Antico, 662
R. Aparicio, 826
P. C. Appelbaum, 373, 814
B. Aracil, 745
F. G. Araujo, 26
A. Archimandritis, 388
J. Arnal, 222
H. Arnesen, 654
O. Assadian, 310
R. Auckenthaler, 419
F. Auquer, 50
V. Ausina, 222
J. L. Avril, 207
A. Aydin, 388
N. Aysuna, 202

A. Başçı, 736
K. Bahar, 606
C. H. Ballow, 791
S. N. Banerjee, 405
C. M. Barberis, 828
M. R. D. Barnham, 174
W. Bartholomew, 182, 189
K. F. Bartizal, 753
S. Bartolome, 182, 189
T. Bathgate, 85
J. Batlle, 50
M. Bayık, 442
A. van Belkum, 187
J. V. Benedí, 397
R. Bercion, 680
B. Bergey, 676
P. Berthelot, 352
D. J. Biedenbach, 340, 791
A. Bilgiç, 736
J. Bille, 419
A. Birinci, 810
M. Bisconti, 358
D. S. Blanc, 419
J. R. Blanco, 763
A. Bolmstrom, 791
M. Boni, 345
T. Bourlet, 352
E. Bouza, 1, 255, 265, 447
L. Boyanova, 388
B. Bozdogan, 373
S. Bozfakioglu, 202
N. van den Braak, 187
T. Bregenzer, 405
U. Brennscheidt, 14
R. Brown, 413
F. M. Brunkhorst, 93
B. Bruun, 38, 122
A. Bryskier, 65, 467
A. G. M. Buiting, 671
A. Burillo, 265
R. G. Burns, 801, 830

M. Célard, 113
M. R. Cömert, 363
J. C. Caballero, 50
F. Cabria, 607
A. Cagatay, 202
S. Calangu, 202
J. Carneado, 826
J. Carratalà, 282
V. Carreño, 74
A. Carricajo, 680
O. Cars, 646
C. Cattoen, 207
J.-M. Cavaillon, 31
J. Cazallas, 115
N. Çerikcioğlu, 442
M. Çetiner, 442
M. Célard, 113
M. Celard, 680
S. Cesur, 606
L. Chalabreysse, 113
H. Chardon, 207
C. Chaux, 641
T. Cheasty, 183
M. Chomarat, 680
E. Cinar, 363
J. M. Cisneros, 687
C. L. Clark, 373
T. P. Close, 243, 248
A. Y. Coban, 810
J. Collazos, 115
A. Colombo, 405
F. Cordón, 50
O. Cornely, 14, 545
J. R. Costa, 125
H. Costopoulos, 806
R. J. Courcol, 758
M. Crepy, 641
J. M. Cristino, 118
I. A. Critchley, 101, 214
J. C. Croix, 207
J. Croizé, 680
E. Cuchí, 609
D. H. Culver, 405
B. A. Cunha, 489

F. Díaz, 115
H. Dabernat, 207
R. Daoud, 405
T. A. Davies, 373
B. Davoust, 345
L. J. Day, 427
F. De Bernardis, 405
J. De la Rubia, 725
J. M. De la Viuda, 115
E. Debbra, 368
C. Debusk, 405
M. Degré, 191, 431
R. Del Prete, 358
F. Delubac, 680
B. B. Dencker, 196
M. Deruytter, 246
C. Des Champs, 405
B. Dewasse, 373
C. Dib, 207
J. T. van Dissel, 70
G. V. Doern, 405, 405
F. Dromer, 31
J. P. Dubey, 634
W. Dunagan, 405
J. Dunkel, 405
B. Durupinar, 810
D. Dzierżanowska, 388

M. Edmond, 405
P. Eggimann, 295
B. Ekinci, 810
F. Elgh, 450, 504
F. Elgh, 522
T. G. Emori, 405
H. D. Engler, 214
K. L. Enguez, 112, 130
V. Epifani, 358
P. Erard, 803
S. Erekul, 606
S. Erensoy, 736
S. Erol, 749
M. Erturk, 810
Y. Esnault, 405
J. Esteban, 607
J. Etienne, 113
A. T. Evangelista, 214
J. Evans, 183
A. Evison-Eckstein, 405

G. Fätkenheuer, 545
D. Fèvre, 680
D. Fındık, 245, 252
A. Famiglietti, 828
I. Fernández, 80
C. Fernández-Gutiérrez, 589
S. Ferranti, 437, 445
J. Feyjoo Casero, 112
A. Figuera, 14
R. Finch, 317
E.-J. Finke, 510

© 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, **8**, 836–839

Author index

H. Abacıoğlu, 736
B. Acosta, 725
C. Adalid, 50
S. A. Adams, 529
S. J. Advani, 551
P. Aerts, 246
J. M. Aguado, 125
K. Ahmed, 55
M. Akova, 240
Y. Akyön, 438
J. I. Alós, 745
A. Al-Aniezi, 734
B. Al-Nawas, 93
M. Aliani, 358
M. N. Almuzara, 828
R. Alonso, 447
B. Altun, 240
V. Anand, 2
A. W. Anderson, 174
A. Andremont, 405
F. Antico, 662
R. Aparicio, 826
P. C. Appelbaum, 373, 814
B. Aracil, 745
F. G. Araujo, 26
A. Archimandritis, 388
J. Arnal, 222
H. Arnesen, 654
O. Assadian, 310
R. Auckenthaler, 419
F. Auquer, 50
V. Ausina, 222
J. L. Avril, 207
A. Aydin, 388
N. Aysuna, 202

A. Başçı, 736
K. Bahar, 606
C. H. Ballow, 791
S. N. Banerjee, 405
C. M. Barberis, 828
M. R. D. Barnham, 174
W. Bartholomew, 182, 189
K. F. Bartizal, 753
S. Bartolome, 182, 189
T. Bathgate, 85
J. Batlle, 50
M. Bayık, 442
A. van Belkum, 187
J. V. Benedí, 397
R. Bercion, 680
B. Bergey, 676
P. Berthelot, 352
D. J. Biedenbach, 340, 791
A. Bilgiç, 736
J. Bille, 419
A. Birinci, 810
M. Bisconti, 358
D. S. Blanc, 419
J. R. Blanco, 763
A. Bolmstrom, 791
M. Boni, 345
T. Bourlet, 352
E. Bouza, 1, 255, 265, 447
L. Boyanova, 388
B. Bozdogan, 373
S. Bozfakioglu, 202
N. van den Braak, 187
T. Bregenzer, 405
U. Brennscheidt, 14
R. Brown, 413
F. M. Brunkhorst, 93
B. Bruun, 38, 122
A. Bryskier, 65, 467
A. G. M. Buiting, 671
A. Burillo, 265
R. G. Burns, 801, 830

M. Célard, 113
M. R. Cömert, 363
J. C. Caballero, 50
F. Cabria, 607
A. Cagatay, 202
S. Calangu, 202
J. Carneado, 826
J. Carratalà, 282
V. Carreño, 74
A. Carricajo, 680
O. Cars, 646
C. Cattoen, 207
J.-M. Cavaillon, 31
J. Cazallas, 115
N. Çerikcioğlu, 442
M. Çetiner, 442
M. Célard, 113
M. Celard, 680
S. Cesur, 606
L. Chalabreysse, 113
H. Chardon, 207
C. Chaux, 641
T. Cheasty, 183
M. Chomarat, 680
E. Cinar, 363
J. M. Cisneros, 687
C. L. Clark, 373
T. P. Close, 243, 248
A. Y. Coban, 810
J. Collazos, 115
A. Colombo, 405
F. Cordón, 50
O. Cornely, 14, 545
J. R. Costa, 125
H. Costopoulos, 806
R. J. Courcol, 758
M. Crepy, 641
J. M. Cristino, 118
I. A. Critchley, 101, 214
J. C. Croix, 207
J. Croizé, 680
E. Cuchí, 609
D. H. Culver, 405
B. A. Cunha, 489

F. Díaz, 115
H. Dabernat, 207
R. Daoud, 405
T. A. Davies, 373
B. Davoust, 345
L. J. Day, 427
F. De Bernardis, 405
J. De la Rubia, 725
J. M. De la Viuda, 115
E. Debbra, 368
C. Debusk, 405
M. Degré, 191, 431
R. Del Prete, 358
F. Delubac, 680
B. B. Dencker, 196
M. Deruytter, 246
C. Des Champs, 405
B. Dewasse, 373
C. Dib, 207
J. T. van Dissel, 70
G. V. Doern, 405, 405
F. Dromer, 31
J. P. Dubey, 634
W. Dunagan, 405
J. Dunkel, 405
B. Durupinar, 810
D. Dzierżanowska, 388

M. Edmond, 405
P. Eggimann, 295
B. Ekinci, 810
F. Elgh, 450, 504
F. Elgh, 522
T. G. Emori, 405
H. D. Engler, 214
K. L. Enguez, 112, 130
V. Epifani, 358
P. Erard, 803
S. Erekul, 606
S. Erensoy, 736
S. Erol, 749
M. Erturk, 810
Y. Esnault, 405
J. Esteban, 607
J. Etienne, 113
A. T. Evangelista, 214
J. Evans, 183
A. Evison-Eckstein, 405

G. Fätkenheuer, 545
D. Fèvre, 680
D. Fındık, 245, 252
A. Famiglietti, 828
I. Fernández, 80
C. Fernández-Gutiérrez, 589
S. Ferranti, 437, 445
J. Feyjoo Casero, 112
A. Figuera, 14
R. Finch, 317
E.-J. Finke, 510

© 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, **8**, 836–839

C. Fitting, 31
M. Flores, 115
M. Forné, 609
Z. F. Forycki, 93
M. P. Foschino Barbaro, 358
T. Fosse, 207
N. Foudraine, 405
I. Frédénucci, 680
P. Francioli, 419
E. Frangoulis, 162
V. Fraser, 405
R. Frei, 405, 419
A. M. Freydiere, 641
A. Fruchart, 758
C. Fuhrmann, 680
J. FyjooCasero, 130

F. R. Gómez, 604, 611
J. L. Gómez-Garcés, 745
V. Göral, 388
D. Gür, 240
B. Gahrn-Hansen, 122
G. Gaitanis, 162
D. A. Gajjar, 229
I. Galani, 579
J. M. García-Lechuz, 669, 684, 739, 760
J. M. García-Lechuz Moya, 604, 611
S. García-Morillo, 826
V. Gauduchon, 113
G. Gemignani, 437, 445
C. Genin, 352
G. Gentile, 405
K. Georgilis, 806
R. Gerardi, 358
G. Gessoni, 662
G. Gesu, 101
J. C. Ghnassia, 207
A. Giacomini, 662
H. Giamarellou, 579
Y. Gille, 641
M. Giménez, 222
J. A. Girón-González, 589
C. Girmenia, 405, 405
M. P. Glauser, 14
M. Gobernado, 725
A. Goglio, 101
F. W. Goldstein, 823
D. Gomez-Pastrana, 541
R. Gonzalez, 773
M. Gordon, 694
E. Gorina, 50
S. E. Gorman, 529
G. Gosciniak, 388
I. M. Gould, 715
W. Graninger, 310
N. Gras, 676
D. M. Grasela, 229
F. Grattard, 352
A. Grigg, 14
R. Grunow, 510
M. Gubina, 388
P. Guido, 358
C. Guney, 363
S. Gupta, 2

T. Hänscheid, 118
J. van Halteren, 671
D. S. Hansen, 38, 397
S. Harbarth, 419
S. A. Harding, 243, 248
G. Hasçelik, 240
R. Havlak, 529
P. D. Heinze, 214
M. Helfre, 680
B. Henriques Normark, 613
C. Hentsch, 803
C. Herrero, 773
P. S. Hicks, 753
D. Hill, 634
P. R. Hira, 734
D. B. Hoellman, 814
R. J. Hollis, 405
E. Holter, 431
A. A. Hoosen, 55
W. Howard, 340
D. Hubbard, 214
S. H. Humphery, 243, 248
M.-O. Husson, 758

T. Ignatiades, 381
L. Improvisi, 31
E. Ingham, 47
S. Ioannou, 405
B. Issartel, 113
K. Ivanova, 388
C. Izzo, 358
J. Iqbal, 734

M. R. Jacobs, 373, 814
I. Jara López, 383
I. Jarque, 725
W. Jarvis, 405
A. G. Jensen, 38
E. S. Jensen, 196
C. Jiménez, 725
M. T. Jiménez de Anta, 791
M. E. Jones, 101, 214
M. Jones, 405
R. N. Jones, 340, 791
R. Jones, 405
R. N. Jones, 405, 405
T. W. Jorgensen, 112, 130

A. Kański, 58
A. Kabani, 405
D. A. Kafetzis, 45, 60
S. Kalenic, 388
K. Kallergi, 45, 60
K. Kanellakopoulou, 579
B. Kantarçeken, 388
H. Kaplan, 736
J. A. Karlowsky, 214
J. Karlowsky, 405
S. Kartı, 442
A. Katsambas, 162
C. A. Kauffman, 427
A. Kaufmann, 479
A. Kaya, 749
R. Kazancioglu, 202
P. M. Keig, 47
L. M. Kelly, 814
K. G. Kerr, 47
C. Keyserling, 14
R. Khatib, 405
A. King, 85
S. A. Klotz, 182, 189
J. Kluytmans, 405
K. D. J. H. Klym, 405
S. Kocagöz, 240
I. H. Kocar, 363
J. Koeleman, 405
H. Kolk, 598
H. J. Kolmos, 397
E. Konstantinou, 381
D. Kontoyannis, 806
V. Korten, 442
D. Korular, 202
K. I. Kristiansen, 431
F. Krummenauer, 93
M. Kujawa, 187
I. Kull, 598
L. Kupcinskas, 388
D. Kvale, 431

A. López-Suárez, 589
K. Lõivukene, 598
E. Löwdin, 646
B. La Scola, 345
K. Labotkin, 598
H. Lagler, 310
K. Lantorp, 522
H. Larsen, 196

J. Le Noble, 405
S. R. Leal Noval, 383
E. Lebessi, 45, 60
E. Lecaillon, 207
N. Legakis, 381
N. J. Legakis, 45, 162
N. J. Legakis, 60
H. Lelièvre, 680
H. Lepidi, 113
Z. Lepsanovic, 709
A. B. Lerkerød, 654
M. N. Letouzey, 680
A. S. Levin, 144
I. Levy, 405
E. P. de la Llave, 604, 611
C. Loïez, 758
C. Logroscino, 358
J. Lopez Longo, 669, 684
O. Lortholary, 31
F. R. Lucht, 352
M. Luczak, 187
C. Lumbreras, 80

F. Mégraud, 676
K. Mühlemann, 419
H.-I. Maaroos, 598
F. M. MacKenzie, 715
J. A. Madueño, 773

© 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, **8**, 836–839

A. Mandjee, 680
F. Manoni, 662
B. Maraha, 671
A. Marchére, 368
F. Marco, 791
M. Marina, 388
A. Marinus, 405
A. Marmonier, 207
A. Martín, 739, 760
G. Martín, 725
J. Martínez, 725
P. Marthelet, 680
J. Martin, 607
C. Martino, 405
P. Martino, 405
G. Martirosian, 58
R. Mas, 363
M. de la Mata, 773
L. Matas, 222
P. Matsiota-Bernard, 381
J. Mattera, 828
J. McCoubrey, 413
P. L. McEvoy, 801, 830
G. Medoff, 405
J. Meis, 405
F. Meisel-Mikolajczyk, 187
R. Meley, 680
F. Mendoza, 115
F. Menichetti, 437, 445
A. Mentis, 388
S. Messer, 405
S. A. Messer, 405
F. Messina, 437, 445
M. L. Mezzatesta, 368
M. Miñambres, 745
G. Miño, 773
C. de Mier, 828
M. Mikelsaar, 598
C. A. Miller, 715
J. Mira, 589
G. Miragliotta, 358
M. Miranda, 826
V. Mirovic, 709
I. Mitov, 388
A. Mitroussia, 162
N. Moniot-Ville, 207
L. Monteiro, 676
P. Moreillon, 419
M. Mori, 405
A. Morris, 405
F. Moscardó, 725
P. Moström, 694
M. Motyl, 753
P. Muñoz, 265

N. Nørskov-Lauritsen, 38
K. Nagai, 373
J. Nanas, 806
E. Navas, 534
J. Ngeh, 2
M. Nguyen, 405
M. H. Nicolas-Chanoine, 207
G. Nicoletti, 368
L. E. Nicolle, 405
G. L. Nielsen, 196
J. Ninet, 113
C. E. Nord, 229
K. P. Nordal, 431
P. Nordmann, 321
S. Normark, 613
M. Nucci, 405
E. Nulens, 455

S. K. Obaro, 623
P. Obuch-Woszczatyński, 187
Z. Odabaşi, 442
I. Odenholt, 646
J. Olalla, 125
G. Ortisi, 101
A. Ortiz, 607
J. Oteo, 745
J. A. Oteo, 763
J. E. Otterstad, 654
T. Özacar, 736
A. Özden, 388
Z. Özkurt, 749

C. Pérez-Bellés, 725
R. Pérez-Cano, ??
E. Pacios, 669, 684
J. A. Paiva, 290
E. Palenque, 125
E. Pamies, 826
I. Paraskakis, 45, 60
A. Pascual, 256
J. Peacock, 405
B. Pelak, 753
J. Pemán, 725
J. M. Pereira, 290
J. R. Perfect, 801, 830
J. D. Perrier-Gros-Claude, 680
T. Peters, 154
C. Petignat, 419
G. Petrikkos, 579
V. Petrocheilou-Paschou, 806
P. Petrov, 388
M. Pfaller, 405
M. A. Pfaller, 405, 405
M. A. Pfaller, 405
I. Phillips, 85
D. Pittet, 295, 419
H. Pituch, 187
G. Pliakas, 381
G. Plumé, 725
L. Poirel, 321
M. Pombo, 125
M. Popova, 388
I. R. Poxton, 413
B. Pozzetto, 352
C. Prat, 222
H. Prifti, 806

Q. J. Qayyum, 427
S. Quintana, 609
A. Qwarnstrom, 791

S. Ragnar Norrby, 448
M. Ramharter, 310
D. Raoult, 345
N. Rastogi, 694
S. Ratip, 442
A. Regadera, 725
J. S. Remington, 26
O. Resta, 358
A. Reyero, ##PAGE##
Y. Rezvani, 207
H. Richet, 405
M. Ridell, 694
E. Riopérez, 125
A. Rivero, 773
E. Rodríguez, 125
F. J. P. Rodríguez, 112, 130
J. *Rodríguez-Baño*, 275, 687
R. Roffey, 450, 522
B. Roizman, 551
H. Rollag, 431
A. Ros, 680
M. de la Rosa, 745
T. Roth, 803
C. Rotstein, 405
C. Roure, 641, 680
M. Roussel-Delvallez, 207
P. Roux, 405
E. Rozynek, 388
L. Rubin, 405
R. Rubio, 80
C. Ruef, 419
J. Ruiz, 791

M. Sánchez-Conde, 739, 760
P. Sánchez-Guijo, 773
H. T. Sørensen, 196
S. Saavedra, 725
H. S. Sader, 405
A. Safdar, 243, 248
A. Safdar, 801, 830
S. Sagedal, 431
S. Sahin, 202
D. F. Sahm, 101, 214
M. J. Salgado, 118
R. Salomao, 405
M. M. Salvadego, 662
F. Santos-O'Connor, 607
G. F. Sanz, 725
M. A. Sanz, 725
A. A. Sayıner, 736
H. C. Schønheyder, 196
A. M. Schito, 368
G. Schmid, 479
A. Schumacher, 654
H. Seifert, 545
P. P. Sein, 55
I. Seljeflot, 654
M. S. Sever, 202
P. M. Shah, 93
M. Shahnawaz, 55
A. Sher, 734
J. M. Sierra, 791
P. Simmonds, 736
J. Sirot, 207
R. Skov, 38, 397
T. L. Slifer, 26

© 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, 8, 836–839

S. Smati, 680
H. R. Smith, 183
C. Sola, 694
L. Sommervoll, 654
S. Sood, 154, 405
C. J. Soussy, 207
V. Sperling, 397
T. Spiritus, 246
S. Stamatelopoulos, 806
G. Stamos, 45, 60
C. S. Stavrinadis, 45, 60
S. Stefani, 368
D. L. Stevens, 133
P. Stiefel, 826
I. Stock, 564
S. Storfer, 405
A. Stuer, 246
P. Sudre, 419
I. Surmont, 246
A. Szczęsny, 58

K. Tack, 14
A. Tanna, 174
C. Tascini, 437, 445
M. A. Tasyaran, 749
D. M. Taylor, 332
A. Tegnell, 450, 504
A. Tegnell, 522
A. Telenti, 137
G. Tempera, 368
J. Thierry, 680
M. Thirumoorthi, 405
C. Thornsberry, 214
E. J. Threlfall, 154
D. S. Tompkins, 183
J. Torre-Cisneros, 773
J. Tous, 680
A. Trevoux, 207
U. Trostmann, 14
P. Tschantz, 803
A. Tsigonia, 162
V. Tucci, 405
A. Turkmen, 202
A. Turrión, 669, 684
A. Tzimogianni, 162

O. Ural, 245, 252
J. C. Urkijo, 115

X. Vallés, 222
I. Vallejo-Maroto, 826
S. Valverde, 662
P. A. R. Vandamme, 47
F. Vandenesch, 113, 207
S. I. Vas, 705
S. Vasinhtha, 405
C. Vay, 828
A. Vcev, 388
A. Velegraki, 162
F. Verduyn Lunel, 405
J. M. Verzijl, 671
J. Vila, 791
C. Viscoli, 405
A. Voss, 405, 455

B. Wahren, 504
F. Wallet, 758
L. R. Ward, 154
R. R. Weichselbaum, 551
N. C. Weightman, 174
L. Welling, 14
R. Wenzel, 405, 405
R. P. Wenzel, 405
S. Wey, 405
J. G. Wheeler, 183
R. J. Whitley, 551
A. F. Widmer, 419
B. Wiedemann, 564
G. A. Willshaw, 183
A. Wilson, 183
F. Wilson, 405
R. G. F. Wintermans, 671
M. B. Wittel, 826
G. L. Woods, 753
R. F. Woolson, 405

E. Xirouchaki, 579
S. Xueref, 641

M. Yücesoy, 413
D. Yamamura, 405
M. Yazici, 363
C. Yeğen, 442

R. Zbinden, 419
A. Zeytinoğlu, 736
G. Zhanel, 405
W. Zimmerli, 405

© 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, **8**, 836–839

Subject index

Abdomen: right lower abdominal pain progressing to acute abdomen (continuing medical education), 112/130
Abscess
  Salmonella enteritidis, behind eye (correspondence), 247
  subpectoral, group B streptococcus (continuing medical education), 684
Acinetobacter, multiresistant infections, role for sulbactam combinations, 144
Acinetobacter baumannii, nosocomial bacteremia, 687
Acquired immunodeficiency syndrome *see* AIDS
Actinomycosis (continuing medical education), 130
Age, influence on course of infection and cytokine responses in disseminated *Cryptococcus neoformans* infection, 31
AIDS
  esophago-airway fistula (continuing medical education), 182/189
  see also HIV infection
Amikacin *see* Ceftazidime plus amikacin
Amoxicillin, *Helicobacter pylori* resistance to, eastern Europe, 388
Amoxicillin/clavulanic acid, pharmacodynamics against *Haemophilus influenzae*, 646
Ampicillin–sulbactam, multiresistant *Acinetobacter* infections, 144
Anaerobes, in vitro anti-anaerobic activity of cephalosporin derivative RWJ 54428 (concise communication), 814
Anthrax
  antibacterial agents, 467
  bioterrorism/biological warfare, 467, 478
    diagnosis and management in emergency room, 489
    laboratory diagnosis, 460
  Europe: epidemiology, clinical characteristics and role in terrorism, 479
Antibiotic resistance
  carbapenemases, 320
  detection of glycopeptide resistance in staphylococci and enterococci, 101
  Helicobacter pylori
    antibiotic consumption and, 598
    eastern Europe, 388
    Estonia, 598
  as result of massive use of agents in bioterrorist attack, 534
  surveillance (editorial), 317
  transferable resistance mechanisms in *Klebsiella pneumoniae*, 579
  viridans streptococci, 65
    effect of azithromycin and clarithromycin, 85
Antibiotic susceptibility
  Arcanobacterium hemolyticum (correspondence), 828
  Bacillus anthracis, 467
  detection of glycopeptide susceptibility in staphylococci and enterococci, 101
  Enterobacteriaceae susceptibility to β-lactam agents and fluoroquinolones, 207
  natural susceptibility of recently established *Enterobacter* spp., 564
  Streptococcus agalactiae strains (concise communication), 745
Antibiotic tolerance, pneumococci, 613
Antibiotics
  β-lactam
    anthrax, 467
    Enterobacteriaceae susceptibility, 207
  streptogramin, in vitro activity against *Streptococcus pneumoniae* strains (concise communication), 680
Antioxidants, effect on immune response to *Helicobacter pylori*, 438
APACHE II score, risk evaluation in severe pneumonia, 93
Arcanobacterium hemolyticum, identification and susceptibility to nine antimicrobial agents (correspondence), 828
Arthritis, septic: *Salmonella* prosthetic joint infection (concise communication), 427
Asthma, chronic, seroprevalence of *Chlamydia pneumoniae* infection, 358
Atherosclerosis
  Chlamydia pneumoniae and, 2, 654
  cytomegalovirus infection and (editorial), 191
Azithromycin
  effect on macrolide resistance of viridans streptococci from normal throat flora, 85
  Streptococcus agalactiae susceptibility (concise communication), 745

© 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases

Bacillus anthracis
antibacterial agents, 467
bioterrorism/biological warfare, laboratory diagnosis, 460
Europe, 479
see also Anthrax
Bartonella detection in stray cat population, 345
Beta-lactamases
emerging carbapenemases in Gram-negative aerobes, 321
extended-spectrum, comparison of screening methods, 715
production in *Staphylococcus aureus*, mecillinam susceptibility as indicator (concise communication), 122
recently established *Enterobacter* spp., 564
Beta-lactams *see* Antibiotics, β-lactam
Biological and Toxin Weapons Convention, 452
Bioterrorism/Biological warfare
anthrax, 467, 479
differentiation of natural and artificial epidemics, 510
historical perspective and world view, 450
laboratory diagnosis and biosafety issues of biological agents, 455
preparedness for, 522
creation of pharmaceutical stockpile, 529, 534
problems of massive use of antimicrobial agents, 534
recognition of agents in emergency room, 489
seriousness of threat (editorial), 448
smallpox 489, 504 (review)
Bladder, parachute appearance, HIV-infected patient (continuing medical education), 604/611
Blood cultures
Brucella melitensis detection by BacT/Alert automated system, 749
evaluation of VITAL automated system, 222
Gram-negative bacilli, direct identification and susceptibility testing using VITEK (GNI+/GNS-GA), 38
Blood transfusion, postoperative infection and (editorial), 383
Bloodstream infection, catheter-related, 294
antibiotic-lock therapeutic technique 282, 270 (review), 310
diagnosis and intravascular treatment, 265
empiric therapy, 275
glycopeptide treatment, 255, 310
overview, 295
pathogenesis, 256
prevention, 301
treatment, 545
BMS-284756
ecological impact on normal intestinal microflora, 229
selection study of antipneumococcal activity (concise communication), 373
in vitro activity, 340
Bone marrow transplantation from unrelated donor, infectious complications, 725
Bovine spongiform encephalopathy (BSE), 332
Brucella, bioterrorism/biological warfare, laboratory diagnosis, 462
Brucella melitensis
detection by BacT/Alert and *Brucella* broth culture (concise communication), 749
in vitro activities of new quinolones (concise communication), 240
Brucellosis (continuing medical education), 253
Burkholderia cepacia complex, differential invasion of respiratory epithelial cells (concise communication), 47

C-reactive protein, risk evaluation in severe pneumonia, 93
Cancer, febrile neutropenia, empirical treatment with clinafloxacin monotherapy versus ceftazidime plus amikacin, 14
Candida infection
catheter-related, clinical management, 545
chronic disseminated, unresponsive to treatment (continuing medical education), 435/442
Candida krusei pneumonia (concise communication), 806
Candidemia, French hospitals, incidence and characteristics, 405
Carbapenemases, Gram-negative aerobes, 320
Cardiac tamponade due to hemorrhagic pericarditis in non-immunocompromised patient (continuing medical education), 243/248
Castleman's disease, detection of Kaposi's sarcoma herpesvirus DNA sequences in pericardial fluid (correspondence), 381
Catheter-related infections (editorial), 255
diagnosis and intravascular treatment, 165
overview, 295
pathogenesis, 256
prevention, 301
new catheter designs, 256

© 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, **8**, 840–848

treatment, 545
afebrile patient after catheter withdrawal, 290
antibiotic-lock technique 270, 282 (review), 310
empiric, 275
glycopeptides in, 310
intravascular, 165
Cephoperazone–sulbactam, multiresistant *Acinetobacter* infections, 144
Cephotaxime, in vitro effects on *Salmonella typhi* within human macrophages (concise communication), 810
Ceftazidime plus amikacin, comparison with clinafloxacin monotherapy in empirical treatment of febrile neutropenic cancer patients, 14
Ceftriaxone, in vitro effects on *Salmonella typhi* within human macrophages (concise communication), 810
Cell adhesion molecules, effect of *Chlamydia pneuomiae* and/or *Helicobacter pylori*, 654
Cellulitis, facial (continuing medical education), 60
Cephalosporin derivative RWJ 54428, in vitro anti-anaerobic activity (concise communication), 814
Cephalosporin resistance, cephalosporinase induction and (correspondence), 823
Cervical mass and fever (continuing medical education), 739/760
Chest wall, right infraclavicular mass in woman with connective tissue disease (continuing medical education), 669/684
Chlamydia pneumoniae
and atherosclerosis, 2, 654
effect on expression of endothelial cell adhesion molecules, 654
levofloxacin activity against, 214
seroprevalence in chronic stable asthma, 358
Chromogenic agar plates, isolation and detection of urinary tract pathogens, 641
Ciprofloxacin
Helicobacter pylori resistance, eastern Europe, 388
single-dose, comparison with 3 days of norfloxacin in urinary tract infection in women (concise communication), 50
use in bioterrorist attack, 534
in vitro activities against *Brucella melitensis* (concise communication), 240
Clarithromycin
effect on macrolide resistance of viridans streptococci from normal throat flora, 85
Helicobacter pylori resistance, eastern Europe, 388
Clinafloxacin (CI-960) monotherapy versus ceftazidime plus amikacin, empirical treatment of febrile neutropenic cancer patients, 14
Clindamycin, *Streptococcus agalactiae* susceptibility (concise communication), 745
Clostridium botulinum in bioterrorism/biological warfare, laboratory diagnosis, 463
Clostridium difficile
toxin A-negative/B-positive strains, variable flagella expression (correspondence), 187
toxin production, detection methods, 413
Connective tissue disease, right infraclavicular mass (continuing medical education), 669/684
Continuing medical education
bladder parachute in an HIV-infected patient, 604/611
cardiac tamponade due to hemorrhagic pericarditis in non-immunocompromised patient, 243/248
chronic disseminated candidiasis unresponsive to treatment, 435/442
esophago-airway fistula in AIDS, 182/189
facial inflammation in child with subnormal serum concentration of IgGU2u, 45/60
fever and cervical mass in 81-year-old woman, 739/760
fever and headache in heavy consumer of eucalyptus extract, 437/445
fever and maculopapular rash in 22-year-old, 245/252
right infraclavicular mass in woman with connective tissue disease, 669/684
right lower abdominal pain progressing to acute abdomen, 112/130
Coronary heart disease, effect of *Chlamydia pneumoniae* and/or *Helicobacter pylori* on expression of endothelial cell adhesion molecules, 654
Coxiella burnetti, testing for, Q fever endocarditis (concise communication), 113
Creutzfeldt–Jakob disease, variant (vCJD), 332
Crush syndrome, infections in, 202
Cryptococcus neoformans, disseminated infection, influence of gender and age on course of infection and cytokine responses, 31
Cryptococcus neoformans var. gattii meningitis (continuing medical education), 445
Cytokines
effect of moxifloxacin on secretion by human monocytes, 26

© 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, **8**, 840–848

responses in disseminated *Cryptococcus neoformans* infection, influence of gender and age, 31
Cytomegalovirus (CMV) infection
atherosclerosis and (editorial), 191
kidney transplant recipients, significance of plasma CMV DNA concentration (concise communication), 431
liver transplant recipients, pre-emptive ganciclovir, 773
Cytometer UF-100 in diagnosis of acute urinary tract infections, 662

Desfluoroquinolone BMS-284756
ecological impact on normal intestinal microflora, 229
selection study of antipneumococcal resistance (concise communication), 373
in vitro activity, 340
Dialysis
continuous ambulatory peritoneal, *Pseudomonas oryzihabitans* peritonitis (correspondence), 607
infections related to prosthetic materials, 705
Doxycycline
anthrax, 467
use in bioterrorist attack, 534

Ebola, diagnosis and management in emergency room, 489
Ehrlichiosis, human granulocytic, Europe, 763
Electrophoresis, pulsed-field gel *see* Pulsed-field gel electrophoresis
Endocarditis
Mycobacterium fortuitum complex (concise communication), 125
Q fever (concise communication), 113
Enterobacter amnigenus/cancerogenus/gergoviae/sakazakii, natural antibiotic susceptibility, 564
Enterobacteriaceae, susceptibility to β-lactam agents and fluoroquinolones, 207
Enterococci, linezolid activity against (concise communication), 368
Ertapenem, in vitro activity against pathogens from lower respiratory tract infections (concise communication), 753
Erythromycin
resistance in viridans streptococci in oral cavities (editorial), 65
normal throat flora after treatment with azithromycin or clarithromycin, 85
Streptococcus agalactiae susceptibility (concise communication), 745
Escherichia coli, vero cytotoxin-producing, infectious intestinal disease (concise communication), 183
Esophago-airway fistula in AIDS (continuing medical education), 182/189
Eucalyptus extract, fever and headache in heavy consumer (continuing medical education), 437/445
Eye, *Salmonella enteritidis* abscess behind (correspondence), 247

Facial inflammation in child with subnormal serum concentration of IgGU2u (continuing medical education), 45/60
Febrile neutropenia
cancer patients, empirical treatment with clinafloxacin monotherapy versus ceftazidime plus amikacin, 14
Turicella otitidis infection in child with acute lymphoblastic leukemia (correspondence), 758
Fever and cervical mass (continuing medical education), 739/760
Fever and headache in heavy consumer of eucalyptus extract (continuing medical education), 437/445
Fever and maculopapular rash in 22-year-old (continuing medical education), 245/252
Fluoroquinolones
activity in methicillin-susceptible and -resistant *Staphylococcus aureus* and investigation of quinolone resistance, 781
anthrax, 467
Enterobacteriaceae susceptibility, 207
in vitro activity against *Streptococcus pneumoniae* strains (concise communication), 680
see also Desfluoroquinolone BMS-284756
Francisella tularensis in bioterrorism/biological warfare, laboratory diagnosis, 461

Ganciclovir, reduction of cytomegalovirus risk in liver transplant recipients, 773
Gatifloxacin, in vitro activities against *Brucella melitensis* (concise communication), 240
GB virus C/hepatitis G virus in semen and saliva of HIV-1 infected men, 352
Gemifloxacin, in vitro activities against *Brucella melitensis* (concise communication), 240

© 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, **8**, 840–848

Gender, influence on course of infection and cytokine responses in disseminated *Cryptococcus neoformans* infection, 31
Gene therapy, use of herpes simplex virus-1, 551
Glycopeptides
  intravascular catheter-related infections, 310
  susceptibility/resistance detection in staphylococci and enterococci, Italian proficiency study, 101
Gram-negative aerobes, carbapenemases, 320
Gram-negative bacilli, direct identification and susceptibility testing from positive blood cultures using VITEK (GNI+/GNS-GA), 38
Grepafloxacin, in vitro activities against *Brucella melitensis* (concise communication), 240

Haemophilus influenzae, pharmacodynamics of amoxicillin/clavulanic acid, 646
Helicobacter pylori
  antibiotic resistance
    antibiotic consumption and, 598
    eastern Europe, 388
    Estonia, 598
  effect on expression of endothelial cell adhesion molecules and atherosclerotic activity, 654
  Helico Blot 2.1 in investigation of virulence properties (concise communication), 676
  immune repsonse to, effect of antioxidants, 438
Hemorrhagic fevers, viral, bioterrorism/biological warfare
  emergency room diagnosis and management, 489
  laboratory diagnosis, 464
Hepatitis C
  chronic, treatment expectations and risks, 74
  HIV-infected patients
    chronicity and evolution of infection, 589
    therapeutic approach, 80
  nosocomial infection in renal transplant center (concise communication), 741
Herpes simplex virus-1 (HSV-1), use in gene therapy, 551
HIV infection
  bladder parachute appearance (continuing medical education), 604/611
  detection of GB virus C/hepatitis G virus in semen and saliva, 352
  hepatitis C in
    chronicity and evolution of infection, 589
    therapeutic approach, 80
  laboratory monitoring, 137
  see also AIDS
Host factors, influence on course of infection and cytokine responses in disseminated *Cryptococcus neoformans* infection, 31
Human herpesvirus 8 (HHV-8), detection of DNA sequences in pericardial fluid in patient with multicentric Castleman's disease (correspondence), 381
Human immunodeficiency virus *see* HIV
Human papillomavirus infection (continuing medical education), 611

Inflammation, facial, child with subnormal serum concentration of IgG_2 (continuing medical education), 45/60
Interferon
  chronic hepatitis C, 74
  pegylated, chronic hepatitis C, 74
Intestinal disease, vero cytotoxin-producing *Escherichia coli* (concise communication), 183
Intestinal microflora, ecological impact of des-F(6)-quinolone BMS-284756, 229

Kala-azar, death from cumulative sodium stibogluconate toxicity (correspondence), 606
Kaposi's sarcoma herpesvirus, detection of DNA sequences in pericardial fluid in patient with multicentric Castleman's disease (correspondence), 381
Ketolides, anthrax, 467
Kidney transplantation
  cytomegalovirus disease in recipients, significance of plasma CMV DNA concentration (concise communication), 431
  nosocomial hepatitis C infection in transplantation unit (concise communication), 741
Klebsiella typing, pulsed-field gel electrophoresis vs O:K-serotyping, 397
Klebsiella pneumoniae, transferable resistance mechanisms, 579

Legionella pneumophila, levofloxacin activity against, 214
Leishmaniasis, visceral, death from cumulative sodium stibogluconate toxicity (correspondence), 606
Levofloxacin activity against
atypical respiratory pathogens, 214
  Brucella melitensis (concise communication), 240
  Streptococcus pneumoniae strains (concise communication), 680

© 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, **8**, 840–848

Lincosamides, *Streptococcus agalactiae* susceptibility (concise communication), 745
Linezolid
activity against staphylococci and enterococci (concise communication), 368
assessment of antimicrobial activity and spectrum in Europe, 791
in vitro activity against *Streptococcus pneumoniae* strains (concise communication), 680
Liver transplant recipients, cytomegalovirus infection, pre-emptive ganciclovir for, 773

Macrolides
anthrax, 467
Streptococcus agalactiae susceptibility (concise communication), 745
susceptibility of viridans streptococci from normal throat flora after treatment with azithromycin or clarithromycin, 85
Malassezia spp., identification from skin scales by PCR-RFLP, 162
Markers of infection (editorial), 70
Mecillinam susceptibility as indicator of β-lactamase production in *Staphylococcus aureus* (concise communication), 122
Meningitis
aseptic, as delayed neurologic complication of murine typhus (correspondence), 826
neonatal, *Pasteurella gallinarum* (concise communication), 55
Methicillin-resistant *Staphylococcus aureus* (MRSA)
decolonization using oral vancomycin and topical mupirocin (concise communication), 671
fluoroquinolone activity and mechanisms of quinolone resistance, 781
molecular epidemiology of predominant clones and sporadic strains in Switzerland and comparison with European epidemic clones, 419
vancomycin treatment, pseudomembranous colitis following (correspondence), 58
Metronidazole, *Helicobacter pylori* resistance to, eastern Europe, 388
Monocytes, cytokine secretion, effect of moxifloxacin, 26
Moxifloxacin
effect on secretion of cytokines by human monocytes, 26
in vitro activity against *Streptococcus pneumoniae* strains (concise communication), 680
MRSA *see* Methicillin-resistant *Staphylococcus aureus*
Mupirocin, topical, MRSA decolonization (concise communication), 671
Mycobacteria, MB/BacT system for recovery from clinical specimens in comparison to Lowenstein–Jensen medium, 709
Mycobacterium chelonae endocarditis (concise communication), 125
Mycobacterium fortuitum complex endocarditis (concise communication), 125
Mycobacterium tuberculosis infection, cervical mass and (continuing medical education), 760
Mycoplasma pneumoniae, levofloxacin activity against, 214

Neutropenic patients
empirical treatment of febrile episodes in cancer patients, clinafloxacin monotherapy versus ceftazidime plus amikacin, 14
Turicella otitidis infection (concise communication), 758
Norfloxacin, 3-day treatment, comparison with single-dose ciprofloxacin in urinary tract infection in women (concise communication), 50
Nosocomial infections
Acinetobacter baumannii, 687
hepatitis C in renal transplant center (concise communication), 741

O:K serotyping, *Klebsiella*, 397
Ofloxacin, in vitro activities against *Brucella melitensis* (concise communication), 240
Oncolysis, use of herpes simplex virus-1, 551

Parvovirus B19 infection, systemic lupus erythematosus and (concise communication), 115
Pasteurella gallinarum neonatal meningitis (concise communication), 55
Penicillin, tolerance in pneumococci, 65
Penicillin G
resistance in viridans group streptococci in oral cavities (editorial), 65
Streptococcus agalactiae susceptibility (concise communication), 745
in vitro activity against *Streptococcus pneumoniae* strains (concise communication), 680
Phenoxymethylpenicillin, safety in pregnancy, 196
Plague, emergency room diagnosis and management, 489

© 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, **8**, 840–848

Plasmodium falciparum, drug-resistant infection in immigrants and non-immune travellers, 734
Plesiomonas shigelloides, pyosalpinx in immunocompetent host (concise communication), 803
Pneumococcus *see Streptococcus pneumoniae*
Pneumonia
  atypical, bioterrorism, 489
  Candida krusei (concise communication), 806
  community-acquired, in vitro activity of ertapenem (concise communication), 753
  severe, risk evaluation, 93
Polymerase chain reaction (PCR)
  identification of *Malassezia* spp., 162
  tuberculosis diagnosis, children (editorial), 541
Postoperative infection, blood transfusion and (editorial), 383
Pregnancy, safety of phenoxymethylpenicillin, 196
Pristinamycin, in vitro activity against *Streptococcus pneumoniae* strains (concise communication), 680
Procalcitonin
  as marker of infection (editorial), 70
  risk evaluation in severe pneumonia, 93
Prosthetic materials, dialysis, infection and, 705
Pseudomonas oryzihabitans peritonitis in continuous ambulatory peritoneal dialysis (correspondence), 607
Pseudomonas stutzeri (continuing medical education), 60
Pulsed-field gel electrophoresis (PFGE)
  combined with single-enzyme amplified length polymorphism, differentiation of multiresistant *Salmonella* typhimurium, 154
  Klebsiella typing, 397
Pyosalpinx caused by *Plesiomonas shigelloides* in immunocompetent host (concise communication), 803

Q fever endocarditis (concise communication), 113
Quinolones, 229
  mechanisms of resistance in methicillin-susceptible and -resistant *Staphylococcus aureus*, 781
  in vitro activities of new quinolones against *Brucella melitensis* (concise communication), 240
  see also Fluoroquinolones
Quinupristin–dalfopristin, in vitro activity against *Streptococcus pneumoniae* strains (concise communication), 680

Rash, maculopapular, with fever (continuing medical education), 245/252
Renal transplantation *see* Kidney transplantation
Respiratory pathogens
  atypical, levofloxacin activity against, 214
  in vitro activity of ertapenem against pathogens from lower respiratory tract infections (concise communication), 753
Ribavirin, chronic hepatitis C, 74
RWJ 54428, in vitro anti-anaerobic activity (concise communication), 814

Salmonella infection, prosthetic joint septic arthritis (concise communication), 427
Salmonella enteritidis, abscess behind eye (correspondence), 247
Salmonella typhi, human macrophages, in vitro effects of cefotaxime and ceftriaxone (concise communication), 810
Salmonella typhimurium, multiresistant, differentiation by combined pulsed-field gel electrophoresis and single-enzyme amplified length polymorphism, 154
Septic arthritis, prosthetic joint, *Salmonella* infection (concise communication), 427
Sex *see* Gender
Single-enzyme amplified length polymorphism (SAFLP) combined with pulsed-field gel electrophoresis, differentiation of multiresistant *Salmonella* typhimurium, 154
Smallpox, bioterrorism/biological warfare, 504
  emergency room diagnosis and management, 489
  laboratory diagnosis, 464
Sodium stibogluconate toxicity (correspondence), 606
Sparfloxacin, in vitro activities against *Brucella melitensis* (concise communication), 240
Staphylococci
  coagulase-negative, management of catheter-related infection, 545
  linezolid activity against (concise communication), 368
Staphylococcus aureus
  β-lactamase production, mecillinam susceptibility as indicator (concise communication), 122
  catheter-related infection, management, 545
  fluoroquinolone activity in methicillin-susceptible and -resistant strains and mechanisms of quinolone resistance, 781

© 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, **8**, 840–848

methicillin-resistant *see* Methicillin-resistant *Staphylococcus aureus*
Stool cultures, possible introduction of rejection criteria (concise communication), 118
Streptococci
group B
subpectoral abscess (continuing medical education), 684
suceptibility to macrolides and lincosamides (concise communication), 745
toxic shock syndrome (editorial), 133
description of 14 cases, 174
viridans
antibiotic-resistant organisms in oral cavities (editorial), 65
macrolide susceptibility of normal throat flora after treatment with azithromycin or clarithromycin, 85
Streptococcus agalactiae see Streptococci, group B
Streptococcus pneumoniae
antibiotic tolerance, 613
protein conjugate vaccine, 623
selection study of antipneumococcal activity of BMS-284756 (concise communication), 373
transference of antibiotic resistance from viridans group streptococci of oral cavities (eidtorial), 65
in vitro activity of new antimicrobial agents against ofloxacin-intermediate and -resistant strains (concise communication), 680
Streptococcus pyogenes, transference of antibiotic resistance from viridans group streptococci of oral cavities (eidtorial), 65
Streptogramins, in vitro activity against *Streptococcus pneumoniae* strains (concise communication), 680
Sulbactam combinations, multiresistant *Acinetobacter* infections, 144
Surveillance, antibiotic resistance (editorial), 317
Systemic lupus erythematosus (SLE), parvovirus B19 infection and (concise communication), 115

Telithromycin, in vitro activity against *Streptococcus pneumoniae* strains (concise communication), 680
Tetracycline, *Helicobacter pylori* resistance to, eastern Europe, 388
Toxic shock syndrome, streptococcal (editorial), 133
description of 14 cases, 174
Toxoplasma gondii: transmission, diagnosis and prevention, 634
Transfusion, blood, postoperative infection and (editorial), 383
Transfusion-associated immunomodulation (TRIM effect), 383
Transfusion-transmitted virus (TTV), prevalence in prostitutes and homosexual men, 363
Transplantation
bone marrow, from unrelated donors, infectious complications, 725
liver, cytomegalovirus infection, pre-emptive ganciclovir, 773
renal
cytomegalovirus infection, significance of plasma CMV DNA concentration (concise communication), 431
hepatitis C infection in transplant unit (concise communication), 741
Tuberculosis
diagnosis in children, use of polymerase chain reaction (editorial), 541
molecular epidemiology, methods used, 694
Tularemia
differentiation of natural and artificial epidemics, 510
emergency room diagnosis and management, 489
Turicella otitidis in bacteremic child with acute lymphoblastic leukemia (correspondence), 758
Typhus, murine, aseptic meningitis and (correspondence), 826

UF-100 cytometer in diagnosis of acute urinary tract infections, 662
Urinary tract infection
comparison of single-dose ciprofloxacin with 3 days of norfloxacin, women (concise communication), 50
diagnosis, UF-100 cytometer in, 662
isolation and detection of pathogens, comparison of three chromogenic agar plates, 641

Vaccine, protein conjugate, pneumococcal infection, 623
Vancomycin
MRSA decolonization (concise communication), 671

© 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, **8**, 840–848

MRSA infection, pseudomembranous colitis following (correspondence), 58
tolerance, pneumococci, 65
Vero cytotoxin-producing *Escherichia coli* (VTEC), infectious intestinal disease (concise communication), 183
Viral hemorrhagic fevers, bioterrorism/biological warfare
emergency room diagnosis and management, 489
laboratory diagnosis, 464
VITAL automated blood culture system, evaluation, 222
VITEK, GNI+/GNS-GA cards, direct identification and susceptibility testing of enteric bacilli from positive blood cultures, 38

Yersinia pestis in bioterrorism/biological warfare, laboratory diagnosis, 462

© 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI*, **8**, 840–848